Compare · CGC vs DFTX
CGC vs DFTX
Side-by-side comparison of Canopy Growth Corporation (CGC) and Definium Therapeutics Inc. (DFTX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CGC and DFTX operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- DFTX is the larger of the two at $4.79B, about 1.7x CGC ($2.86B).
- DFTX has been more active in the news (20 items in the past 4 weeks vs 13 for CGC).
- CGC has more recent analyst coverage (19 ratings vs 7 for DFTX).
- Company
- Canopy Growth Corporation
- Definium Therapeutics Inc.
- Price
- -
- -
- Market cap
- $2.86B
- $4.79B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 13
- 20
- Recent ratings
- 19
- 7
Canopy Growth Corporation
Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and hemp-based products for recreational and medical purposes primarily in Canada, the United States, and Germany. It operates through two segments, Global Cannabis and Other Consumer Products. The company's products include dried cannabis flowers, oils and concentrates, and softgel capsules. It offers its products under the Tweed, Quatreau, Deep Space, Spectrum Therapeutics, First & Free, TWD, This Works, BioSteel, DNA Genetics CraftGrow, Tokyo Smoke, DOJA, Van der Pop, and Bean & Bud brands. The company also provides growth capital and a strategic support platform that pursues investment opportunities in the global cannabis sector. Canopy Growth Corporation has a clinical research partnership with NEEKA Health Canada and NHL Alumni Association to examine the efficacy of CBD-based therapies as part of the mitigation of persistent post-concussion symptoms. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation is headquartered in Smiths Falls, Canada.
Latest CGC
- SEC Form DEFA14A filed by Canopy Growth Corporation
- Director Yanofsky Theresa sold $13,828 worth of shares (14,920 units at $0.93), decreasing direct ownership by 10% to 131,495 units (SEC Form 4) to satisfy withholding obligation
- Director Lazzarato David Angelo sold $20,742 worth of shares (22,380 units at $0.93), decreasing direct ownership by 11% to 189,479 units (SEC Form 4) to satisfy tax liability
- Director Bayern Joseph sold $2,869 worth of shares (3,096 units at $0.93), decreasing direct ownership by 2% to 142,031 units (SEC Form 4) to cover withholding tax
- Director Atkins M Shan sold $2,869 worth of shares (3,096 units at $0.93), decreasing direct ownership by 2% to 143,421 units (SEC Form 4) (for withholding tax)
- Canopy Growth Appoints Sebastian Blöte as Country Manager for Germany
- SEC Form DEFA14A filed by Canopy Growth Corporation
- Canopy Growth Announces Adjournment of 2026 Annual General and Special Meeting Due to Lack of Quorum
- Canopy Growth Announces Extension of Proxy Voting Deadline for 2026 Annual General and Special Meeting
- Canopy Growth Expands European Medical Cannabis Supply Into the UK
Latest DFTX
- Chief Medical Officer Karlin Daniel sold $396,894 worth of shares (10,853 units at $36.57) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 792,846 units (SEC Form 4) (withholding obligation)
- Chief Executive Officer Barrow Robert sold $1,153,784 worth of shares (31,550 units at $36.57) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 2,213,090 units (SEC Form 4) (for withholding tax)
- Chief Commercial Officer Wiley Matthew T. sold $113,257 worth of shares (3,097 units at $36.57) as part of a pre-agreed trading plan, decreasing direct ownership by 0.86% to 359,036 units (SEC Form 4) (for tax liability)
- Chief Legal Officer Sullivan Mark sold $513,845 worth of shares (14,051 units at $36.57) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 494,228 units (SEC Form 4) to satisfy withholding tax
- Chief Financial Officer Roberts Brandi sold $123,497 worth of shares (3,377 units at $36.57) as part of a pre-agreed trading plan, decreasing direct ownership by 0.85% to 394,528 units (SEC Form 4) (withholding tax)
- Definium Therapeutics Announces New Employee Inducement Grants
- SEC Form 144 filed by Definium Therapeutics Inc.
- SEC Form 144 filed by Definium Therapeutics Inc.
- SEC Form 144 filed by Definium Therapeutics Inc.
- Director Vallone Carol A exercised 1,086 shares at a strike of $35.52, increasing direct ownership by 5% to 22,296 units (SEC Form 4)